David Hall Discusses Six Month Results from Phase I/IIa Clinical Trial
RepliCel President and CEO, David Hall, discusses the Company’s first-in-man clinical trials testing the safety and efficacy of the RepliCel™ technology in men and women with androgenetic alopecia (pattern baldness). This six-month post-injection data supports the continued development of dermal sheath cup cells for the treatment of androgenetic alopecia. It will be used to develop the Investigational Medicinal Product Dossier that will support RepliCel’s application to conduct a Phase IIb dosing trial.
Learn About the Company
Meet David Hall — CEO, President & Director of RepliCel, and Dr. Rolf Hoffmann, MD — Chief Medical Officer & Director at RepliCel. The two experts discuss their vision for RepliCel.
Learn About the Science
Dr. Rolf Hoffmann and David Hall discuss RepliCel’s autologous cell implantation technology using dermal sheath cup cells.
David Hall interviewed by Tobin Smith
Comments are closed, but trackbacks and pingbacks are open.